Trials / Completed
CompletedNCT02388061
Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke
Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- Neuroscience Trials Australia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients presenting to the emergency department with acute ischemic stroke, who are are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for major vessel occlusion to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomised 50:50 using central computerised allocation to intravenous alteplase or tenecteplase before all participants undergo intra-arterial clot retrieval. The trial is prospective, randomised, open-label, blinded endpoint (PROBE) design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenecteplase | |
| DRUG | Tissue Plasminogen Activator |
Timeline
- Start date
- 2015-03-23
- Primary completion
- 2017-10-16
- Completion
- 2018-02-01
- First posted
- 2015-03-13
- Last updated
- 2018-03-30
Locations
18 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT02388061. Inclusion in this directory is not an endorsement.